A federal jury in Chicago has ordered the pharmaceutical company AbbVie Inc. to pay a Tennessee man more than $140 million as compensation for a heart attack he claimed was caused by his taking the testosterone-replacement drug AndroGel.
The Oct. 5 verdict, first reported by Reuters, was delivered after a mistrial was declared in June when one of plaintiff Jeffrey Konrad’s lead attorneys became ill.
The pharmaceutical company said it planned to appeal. Another of Konrad’s lawyers, David Buchanan of the New York office of Seeger Weiss, could not be reached for comment Monday.
Konrad’s lawsuit, filed in 2015, is one of about 6,000 similar cases pending against the Lake Bluff, Illinois-based AbbVie before U.S. District Judge Matthew Kennelly of the Northern District of Illinois.
The verdict included $140 million in punitive damages and $140,000 in compensatory damages, according to the judgment.
Plaintiffs are alleging that AndroGel can cause heart attacks, strokes and other injuries.
AbbVie has said that its marketing of AndroGel adhered strictly to uses approved by the Food and Drug Administration, and that it was in full compliance with applicable standards.
Konrad, 56, had been using AndroGel for two months in 2010 when he suffered a heart attack. He has since recovered from his injuries, according to the lawsuit.
The company contended in court papers that Konrad’s heart attack was caused by other factors, such as obesity and high blood pressure. AbbVie also said it made no misrepresentations about AndroGel’s safety.
AbbVie’s AndroGel is one of the dominant testosterone treatments on the market, with sales of $675 million in 2016, Reuters reported.
AbbVie was created in 2013 as an offshoot of Abbott Laboratories.
Contact the reporter at firstname.lastname@example.org.